In the ECOG 1684 trial that randomized patients with resected stage IIB–III (AJCC 6th edition) melanoma to treatment with IFN alfa‐2b vs. observation, the 5‐year OS rates (95% CI) were 46% (39–55%) and 37% (30–46%), respectively.18 The gene discussed is IFNA1; the disease is melanoma.